MIRM Mirum Pharmaceuticals Inc
Company Analysis
Latest News
Mirum's Revenue Surge and Raised Outlook Spark an 11% Rally — But Can a Money-Losing Drugmaker Sustain the Momentum?
Shares of Mirum Pharmaceuticals jumped 11.1% to $96.73 after the rare-liver-disease specialist posted third-quarter sales that outran Wall Street expectations...
🟢 Mirum Pharmaceuticals is trading 11.15% up today after Q3 sales beat estimates and outlook rose
Mirum Pharmaceuticals is trading 11.15% higher at $96.73 after reporting third-quarter sales above estimates and raising its 2026 sales outlook. - Q3 net...
🟢 Mirum Pharmaceuticals is trading 4.41% up on November 4, 2026, after Q3 revenue beat estimates and guidance rose
Mirum Pharmaceuticals is trading at $90.87, up 4.41%, after third-quarter revenue beat estimates and management raised 2026 product-sales guidance. -...
Mirum Pharmaceuticals third quarter 2026 revenue of $185.7M beat estimates as 2026 sales guidance was raised
Mirum Pharmaceuticals reported third quarter 2026 financial results characterized by a 40% year-over-year increase in total revenue, outperforming analyst...
🟢 Mirum Pharmaceuticals is trading 12.4% up in pre-market ahead of November 3 third-quarter results
Mirum Pharmaceuticals is trading at $95.50, up 12.35% in pre-market, with its upcoming third-quarter report potentially drawing investor attention. - The...
Mirum Pharmaceuticals Inc Q3 2026 Earnings Preview: What Analysts Expect on November 03, 2026
Mirum Pharmaceuticals is projected to report Q3 2026 revenue of $178.07 million and an EPS loss of $0.53, with shares currently trading at $86.00 relative to a...
🟢 Mirum Pharmaceuticals is trading 5.7% up in pre-market after PROGRESS results showed lesion-volume decline
Mirum Pharmaceuticals is trading at $88.00, up 5.68% in pre-market after positive Cohort 2 results from its pivotal PROGRESS study. - Announced October 26, the...
Mirum Pharmaceuticals Announces Positive Pivotal Trial Data for ATEBRIOZ in Pediatric FOP
Mirum Pharmaceuticals announced positive results from Cohort 2 of its pivotal PROGRESS study evaluating ATEBRIOZ (zilurgisertib) in pediatric patients aged 6...
🔴 Mirum Pharmaceuticals is trading 4.1% down today alongside biotech weakness; no clear company-specific catalyst
Mirum Pharmaceuticals is trading at $82.55, down 4.08%, alongside broader biotech weakness; however, no clear company-specific catalyst was identified. - XBI...
Mirum Pharmaceuticals Announces Positive Phase 3 LIVMARLI Data for Cholestatic Liver Diseases
Mirum Pharmaceuticals announced positive topline results from its Phase 3 EXPAND study for LIVMARLI (maralixibat) in treating cholestatic pruritus (itchiness)...
🔴 Mirum Pharmaceuticals is trading 4% down
Mirum Pharmaceuticals is trading at $82.56, down 4.01%; no reliable report links the decline to the study data. - The company announcement confirms an October...
🟢 Mirum Pharmaceuticals is trading 4.15% up in pre-market ahead of Oct. 12, 2026 results call
Mirum Pharmaceuticals is trading at $89.58, up 4.15%, ahead of an investor call on topline Phase 3 EXPAND results. - The call is scheduled for October 12,...
🟢 Mirum Pharmaceuticals is trading 5.5% up today after RBC raised its target to $155
Mirum Pharmaceuticals is trading higher after RBC Capital raised its price target to $155 from $135, with shares at $85.85 (+5.53%) on October 9, 2026. - RBC...
🟢 Mirum Pharmaceuticals is trading 4.3% up today
Mirum Pharmaceuticals is trading at $82.66, up +4.30%, with the cause of the October 7 move unclear. - No verified company announcement or other clear...
🔴 Mirum Pharmaceuticals is trading 4% down with no identified catalyst
Mirum Pharmaceuticals is trading 4.0% down now at $78.17, with no specific catalyst identified; broader biotech weakness may be contributing. - No...
Mirum Pharmaceuticals Gets $195 Target After Positive Phase 3 HDV Data
H.C. Wainwright raised its price target for Mirum Pharmaceuticals to $195 from $140 and maintained a Buy rating. The move followed positive topline results...
MIRM Announces FDA Approval for Atebrioz and Positive Phase 3 Data for Brelovitug
Mirum Pharmaceuticals announced two significant pipeline updates: the U.S. FDA approval of Atebrioz™ (zilurgisertib) for fibrodysplasia ossificans progressiva...
🔴 Mirum Pharmaceuticals is trading 4.1% down with no verified company-specific catalyst
Mirum Pharmaceuticals is trading 4.06% down at $86.06, with no verified company-specific announcement explaining the decline. - The company had scheduled a...
Bank of America Buys $65.8 Million Mirum Stake, Defying Insider Sales
Bank of America Corp DE acquired 561,724 shares of Mirum Pharmaceuticals for approximately $65.8 million. This purchase represents a 0.87% ownership stake in...
🔴 Mirum Pharmaceuticals is trading 4.03% down today — no fresh company-specific catalyst identified
Mirum Pharmaceuticals is trading 4.03% down at $94.84, with no fresh company-specific announcement or clearly reported September 18, 2026 catalyst...